Cutia Therapeutics

HKSE 2487.HK

Cutia Therapeutics EBIT for the year ending December 31, 2023: USD -275.96 M

Cutia Therapeutics EBIT is USD -275.96 M for the year ending December 31, 2023, a -243.69% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Cutia Therapeutics EBIT for the year ending December 31, 2022 was USD -80.30 M, a -59.93% change year over year.
  • Cutia Therapeutics EBIT for the year ending December 31, 2021 was USD -50.21 M.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
SV Wall Street
HKSE: 2487.HK

Cutia Therapeutics

CEO Ms. Lele Zhang
IPO Date June 12, 2023
Location China
Headquarters Huanzhi Building
Employees 360
Sector Consumers Staples
Industries
Personal Care Biotechnology Cosmetics Drugstores & Retail Pharmacies Pharmaceuticals
Description

Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.

StockViz Staff

February 3, 2025

Any question? Send us an email